titumor effects of Linomide. In an editorial accompanying the article by Joseph and Isaacs, Wahl and Kleinman (2) suggested, on the other hand, that tumor therapy protocols that combine Linomide with the antiangiogenic cytokine interleukin 12 (IL-12)-which induces interferon-gamma release and activates rather than inhibits TAMs-would be worth pursuing.
The results of our present studies demonstrate the pertinence of this suggestion. In a murine melanoma model, in which the antitumor activity of Linomide has already been demonstrated (3), we show that administration of IL-12 in combination with Linomide results in potentiated antitumor effects over single-agent therapy (two-sided P<.05; Mann-Whitney U test) (Fig. 1) .
To confirm that IL-12 and Linomide, used alone or in combination, exert the antiangiogenic effects that were expected on the basis of previous reports, we used a tumor-induced angiogenesis model. This model was proven effective in a previous study of IL-12 and tumor necrosis factor (5). Short-term (3 consecutive days) intraperitoneal administration of either 0.1 g IL-12 or 400 mg Linomide resulted in significant inhibition of blood vessel formation at the site of B16F10 murine melanoma cell injection (16. 4 
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We thank Dabrowska and colleagues for their efforts in demonstrating that the combination of interleukin 12 (IL-12) with Linomide® potentiated the antiangiogenic and antitumor effects of each monotherapy in a murine melanoma model. IL-12 released by activated macrophages is an inducer of interferon gamma (IFN-␥) and indirectly of inter- Fig. 1 . Effects of treatment with interleukin 12 (IL-12) and/or Linomide® on B16F10 melanoma growth (IL-12 was a gift from the Genetics Institute Inc., Boston, MA, and Linomide was a gift from Pharmacia and Upjohn, Lund, Sweden). B6D2F 1 mice were inoculated with 1 × 10 6 melanoma cells in the footpad of the right hind limb and treated intratumorally with 0.1 g IL-12 for 7 consecutive days and/or intraperitoneally with 400 mg/kg of Linomide for 21 days starting on day 7 after inoculation of tumor cells. As a control, the following diluents were used: 0.1% bovine serum albumin-phosphate-buffered saline (PBS) administered intratumorally for 7 consecutive days and 0.01% Tween in PBS administered intraperitoneally for 21 consecutive days. Groups consisted of seven to eight mice. Doses of IL-12 and Linomide were established in previous experiments (data not shown). Tumor growth was monitored as described previously (4) . Tumor volumes are expressed as means with 95% confidence intervals. * = two-sided P <.05 as compared with all other groups (Mann-Whitney U test). ࡗ ‫ס‬ control; ᭹ ‫ס‬ IL-12; ᮀ ‫ס‬ Linomide; and ᭞ ‫ס‬ IL-12 + Linomide.
feron IFN-␥-inducible protein (IP-10), which inhibits angiogenesis. IP-10 and Linomide inhibit different steps in the angiogenic process. IP-10 inhibits the differentiation of endothelial cells into tube-like structures but does not affect endothelial cell proliferation, migration, or invasion (1) . On the other hand, Linomide inhibits endothelial cell proliferation, migration, and invasion (2) . In addition, IL-12 inhibits tumor cell production of vascular endothelial growth factor (VEGF) through IFN-␥ while Linomide does not inhibit VEGF production by tumor cells (3,4) . Thus, Linomide and IL-12 appear to have different, but complementary, mechanisms of action, which results in potentiated antitumor effects when they are combined.
It is interesting to note that the authors administered Linomide intraperitonially at a dose of 400 mg/kg. We have demonstrated better antiangiogenic and antitumor effects in our human prostate cancer xenograft models when Linomide was administered orally at a much lower dose (5). This observation indicates that the oral route of administration is more effective than the parental route for mice. The authors could have achieved optimal antitumor effects had they administered Linomide in drinking water.
It is also interesting to note that, when Linomide or IL-10 monotherapy was terminated on day 21 after tumor inoculation, the subsequent tumor growth was enhanced. In contrast, in the combination group, the subsequent rate of tumor growth was not enhanced following termination of treatments. We also have observed similar effects with Linomide in our rodent prostate cancer models, suggesting that Linomide needs to be administered at least intermittently (6).
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